Cantor Fitzgerald raises Cigna stock price target on specialty growth

Cantor Fitzgerald raised its price target on Cigna to $340 from $325 while maintaining an Overweight rating, citing Evernorth Specialty & Care, a recovering Pharmacy Benefits segment, and improved focus after the HIX divestiture. Cigna also posted Q1 2026 EPS of $7.79 versus $7.61 expected and revenue of $68.52 billion versus $66.2 billion expected, with improved full-year guidance. The main caution is the lack of a near-term catalyst, though the September 2026 Investor Day could renew investor interest.

Analysis

The market is still treating CI like a low-multiple health insurer, but the real setup is a self-help capital allocation story with a delayed rerating trigger. With the operating mix being tilted further toward non-government exposure and specialty/pharmacy recovery stabilizing, the key second-order effect is margin durability rather than headline revenue growth; that supports buybacks compounding per-share value even if top-line growth stays mid-single digit. The valuation gap is large enough that even modest confidence in a cleaner 2026 growth algorithm can drive multiple expansion before earnings revisions fully catch up.

The main risk is that this remains a “show-me” name: absent a near-term catalyst, the stock can stay trapped in a value discount despite improving fundamentals. That makes the September 2026 Investor Day more important than it looks; it could become the first point where management is forced to quantify the post-portfolio-shaping growth bridge, and the market will likely reprice the stock months ahead of that if KPI momentum stays intact. Conversely, any renewed noise around pricing, client retention, or reimbursement pressure in PBM would quickly compress the multiple because the bull thesis depends on restored credibility, not just cheapness.

From a relative-value standpoint, CI looks better as a medium-horizon compounder than as a momentum trade. The buyback intensity lowers the fundamental downside, but the lack of a sharp earnings inflection means upside is likely path-dependent: a gradual rerating rather than a short squeeze. The contrarian read is that the market may be underestimating how much a cleaner business mix can improve earnings quality and reduce the regulatory headline discount, which matters more for the multiple than another quarter of small EPS beats.

Key Decisions for Investors

• Long CI vs. UNH or HUM in a 6-12 month relative-value pair: CI has the cleaner self-help/buyback story and less headline overhang, while the multiple still prices in skepticism. Use any post-earnings dip to enter; target 10-15% relative outperformance if execution remains steady.
• Add CI on weakness for a 9-18 month hold. Risk/reward favors patient accumulation because downside is cushioned by repurchases and cheap valuation, while rerating potential to the low-to-mid teens P/E offers 15-25% upside without heroic growth assumptions.
• Sell near-dated upside calls against a long CI equity position for income over the next 1-2 quarters. The stock lacks a near-term catalyst, so implied volatility can be harvested while waiting for the 2026 narrative to mature.
• Monitor PBM renewal commentary and rebate-free model adoption as the key catalyst window over the next 2-3 quarters; if client churn stays contained, consider adding size because the market will likely move before consensus earnings do.
• Do not chase on strength into the Investor Day date. Better risk/reward is to own the stock before the event, then reassess after management gives a quantified long-term algorithm and the market tests whether the rerating is real.